Design, synthesis, and biological evaluation of diaminopyrimidine derivatives as novel focal adhesion kinase inhibitors.
Yixiang SunZixuan GaoRuifeng WangGuoqi ZhangTianxiao WuWenbo YinYin SunQiaohua QinDongmei ZhaoMaosheng ChengPublished in: RSC medicinal chemistry (2023)
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that belongs to the family of focal adhesion complexes and is responsible for the development of various tumors. Herein, 24 diaminopyrimidine derivatives were designed and synthesized based on TAE-226. Several compounds with good activity were further evaluated regarding their antiproliferative activities against two cancer cells with high FAK expression. Compound A12 showed potent anticancer activity against A549 and MDA-MB-231 cell lines with IC 50 values of 130 nM and 94 nM, respectively. In vitro metabolic stability and cytochrome P450 (CYP) inhibition assays showed that A12 exhibited favorable stability and weak inhibitory activity on CYP isoforms. Preliminary evaluation of kinase selectivity showed that A12 was a multi-kinase inhibitor. The acute toxicity in vivo indicated that A12 possessed acceptable safety. Compound A12 was also selected for molecular docking studies and the prediction of molecular properties and drug-like properties. These results indicated that compound A12 could be used as a potential lead compound targeting FAK for further development.
Keyphrases
- tyrosine kinase
- molecular docking
- cell migration
- epidermal growth factor receptor
- biofilm formation
- binding protein
- photodynamic therapy
- liver failure
- molecular dynamics simulations
- oxidative stress
- protein kinase
- cancer therapy
- intensive care unit
- signaling pathway
- cell adhesion
- high throughput
- long non coding rna
- extracorporeal membrane oxygenation
- cystic fibrosis
- climate change
- oxide nanoparticles
- case control
- cell cycle arrest